Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), effectively neutralises Alpha and Delta variants of COVID-19, according to the studies recently conducted by the US National Institute of Health (NIH). The organization said that this claim is being made on the basis of the data of two types of research.
Let us tell you that the Alpha variant was first identified in the UK. Meanwhile, the Delta variant was first identified in India. The NIH said two studies conducted on the blood serum of people, who received Covaxin. Meanwhile, their results showed that the vaccine produces antibodies that effectively neutralize the alpha (B.1.1.7) and delta (B.1.617) variants of SARS-CoV 2.
According to NIH, "The results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively. Meanwhile, an adjuvant developed with funding from the NIH has contributed to the success of Covaxin Covid-19 vaccine. It roughly 25 million people have received to date in India and elsewhere."
The study also revealed, "Meanwhile, unpublished interim results from the phase 3 trial indicate that the vaccine has 78 percent efficacy against symptomatic disease, 100 percent efficacy against severe Covid-19, including hospitalisation, and 70 percent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes Covid-19."
At the same time, Anthony S Fauci said, "Ending a global pandemic requires a global response. I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious Covid-19 vaccine available to people in India."